Oxethazaine

Oxethazaine is amide anesthetic, witha prolong duration of action. Oxethazaine is designated as N, N-bis-(N-methyl-N-phenyl-butyl-acetamide)-betahydroxyethylamine. Oxethazaine is given by mouth along with antacid for the symptomatic relief of gastro-oesophageal reflux disease. Oxethazaine is also used in the ointments and suppositories for the relief of pain associated with haemorrhoids.

Brands
OXYMAG DICAINE DICAINE THAZI GASTROGEL MUCAINE MUCAINE MAGNOFIT JUVACAINE ANTACID AKSOCAIN HICAINE ALUCAINE ALUCAINE ASICIAN FIROLA SULCAIN-M REMOCAIN LOZANE LOZANE UCAINE GASTRICK GASTRICK AUCAIN PEPCAN
Adult Dose
Dose: 5 to 10 mg
Single Dose: 7.5 (7.5)
Frequency: 8 hourly
Route: PO
Instructions:
Neonatal
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Paedriatic
Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group
Characteristics
belongs to Phenyl Acetamide. . The Molecular Weight of Oxethazaine is 467.60.
Contraindications
Oxethazaine is contraindicated in conditions like Hypersensitivity to any component of product.
Effects
The signs and symptoms that are produced after the acute overdosage of Oxethazaine include Drowsiness, Dizziness, Fainting.The symptomatic adverse reactions produced by Oxethazaine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Pruritus, Hypersensitivity reactions, Glossitis, Idosyncratic rashes.
Indications
Oxethazaine is primarily indicated in conditions like Esophagitis, Oesopghagitis, Reflux oesophagitis, and can also be given in adjunctive therapy as an alternative drug of choice in Haemorrhoids, Hemorrhoids.
Interactions
No data regarding the interactions of Oxethazaine was found.
Interfrence
Monitoring of Serum phosphate levels
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tab Protect from Sunlight and Heat.
Warnings
The use of magnesium-containing antacids in patients with mild to moderate renal impairment should be carefully monitored due to a possible increased danger of hypermagnesemia. Hypophosphatemia may occur with prolonged administration or large doses of aluminum-containing antacids (except aluminum phosphate) especially in patients with an inadequate dietary intake of phosphorus.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.